Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Kathrin Stangelberger"'
Autor:
Joséphine Muller, Arnold Bolomsky, Sophie Dubois, Elodie Duray, Kathrin Stangelberger, Erwan Plougonven, Margaux Lejeune, Angélique Léonard, Caroline Marty, Ute Hempel, Frédéric Baron, Yves Beguin, Martine Cohen-Solal, Heinz Ludwig, Roy Heusschen, Jo Caers
Publikováno v:
Haematologica, Vol 103, Iss 8 (2018)
Multiple myeloma bone disease is characterized by an uncoupling of bone remodeling in the multiple myeloma microenvironment, resulting in the development of lytic bone lesions. Most myeloma patients suffer from these bone lesions, which not only caus
Externí odkaz:
https://doaj.org/article/43a3ed5b0efb4ca4a7bad8fc9e723694
Autor:
Arnold Bolomsky, Roy Heusschen, Karin Schlangen, Kathrin Stangelberger, Joséphine Muller, Wolfgang Schreiner, Niklas Zojer, Jo Caers, Heinz Ludwig
Publikováno v:
Haematologica, Vol 103, Iss 2 (2018)
Treatment of high-risk patients is a major challenge in multiple myeloma. This is especially true for patients assigned to the gene expression profiling-defined proliferation subgroup. Although recent efforts have identified some key players of proli
Externí odkaz:
https://doaj.org/article/943488d6d6964a00bd8d4668f8adeb09
Autor:
Arnold Bolomsky, Joséphine Muller, Roy Heusschen, Wolfgang Schreiner, Jo Caers, Kathrin Stangelberger, Heinz Ludwig, Niklas Zojer, Karin Schlangen
Publikováno v:
Haematologica
Treatment of high-risk patients is a major challenge in multiple myeloma. This is especially true for patients assigned to the gene expression profiling-defined proliferation subgroup. Although recent efforts have identified some key players of proli
Autor:
Art Branstrom, Kathrin Stangelberger, Jo Caers, Niklas Zojer, Arnold Bolomsky, Elodie Duray, Christina Pfeiffer, Margaux Lejeune, Louise Vrancken, Marla Weetall, Heinz Ludwig, Helene Breid, Joséphine Muller, Wolfgang Hübl, Martin Willheim
Publikováno v:
British journal of haematologyReferences. 190(6)
Future progress in the treatment of multiple myeloma (MM) requires both the characterisation of key drivers of the disease and novel, innovative approaches to tackle these vulnerabilities. The present study focussed on the pre-clinical evaluation of
Autor:
Arnold Bolomsky, Fred K. Gruber, Boris Hayete, Heinz Ludwig, Dominik Arnold, Puja Raut, Leon Furchtgott, Niklas Zojer, Diane Wuest, Nikhil C. Munshi, Karl Runge, Kathrin Stangelberger, Iya Khalil
Publikováno v:
Blood. 132:3210-3210
Introduction Regardless of significant advances in the therapy of multiple myeloma (MM) there is still a lack of effective treatment options for patients with high-risk disease. In this context, we recently developed a network of high-risk disease ba